Lohocla is a preclinical-stage company focused on the therapy and diagnosis of pain, psychiatric and addictive disorders. The lead product, DCUK, is a patent protected, novel compound that has demonstrated biological activity in animals for pain, anxiety, and alcohol dependence. The lead indication is severe chronic pain. The pain management market is over $32 billion in the USA, and current medications are suboptimal. To date DCUK has been shown to be safe, and to have significant activity for severe pain. Lohocla is currently conducting preclinical FDA studies to pursue potential indications for phantom limb pain, cancer pain, and dental pain. The mission of Lohocla Research Corporation (Lohocla) is to use genomic, proteomic, and gene array technology in conjunction with rational drug design for development of diagnostic and therapeutic products in the area of mental illness and/or addictive disorders. Examples of Lohocla research and development efforts include medications for chronic pain syndromes, including neuropathic pain due to diabetes and cancer chemotherapy. Development of medications valuable in retarding cancer metastasis and a plant extract efficacious in treatment of major depressive illness and tobacco addiction.
